Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Beta 3 Agonist Mirabegron on Erectile Function on Patients With Benign Prostate Hyperplasia

NCT04503850 is registered in ClinicalTrials.gov with Kasr El Aini Hospital as lead sponsor.

NCT NCT04503850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04503850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Beta 3 Agonist Mirabegron on Erectile Function on Patients With Benign Prostate Hyperplasia
Lead sponsor
Kasr El Aini Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2020
Completion date
October 1, 2021
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

males with benign prostatic hyperplasia symptoms